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ABSTRACT 
Context Traditional surgical principles state that pancreatic resection should not be contemplated when malignancies arise in the 
pancreas and involve other organs. While this is logic for ductal adenocarcinoma and other tumours with aggressive biological 
behavior; for even large neuroendocrine tumours, aggressive multivisceral resection may achieve useful palliation and excellent 
survival. Design Case records were retrospectively analyzed. Patients and interventions Twelve consecutive patients (7 males, 5 
females; median age 57 years, range: 37-79 years) underwent multi-visceral en bloc resections for neuroendocrine tumour arising in 
the pancreas between 1994 and 2008. Results Three patients underwent pancreaticoduodenectomy; 9 patients had left sided 
pancreatic resections for neuroendocrine tumour of median diameter 9.5 cm ( 5-25 cm). They had a median of 3 (range: 1-4) 
additional organs resected. There were no post-operative deaths or late mortality with median follow up of 24 months. Five patients 
experienced a complication (major in 3 patients). Median disease free survival was not attained and 3 patients experienced recurrent 
disease mostly in the liver and may be candidates for further resection. Conclusion Aggressive multi-visceral resection for locally 
advanced neuroendocrine tumour involving the pancreas is technically feasible and in selected patients can be achieved with low 
mortality and acceptable morbidity, offering good disease free and overall survival. However this complex surgery should be only 
performed in specialist centers. 
 
INTRODUCTION 
 
Pancreatic resection for tumours involving the pancreas 
is still considered a complex and challenging intra-
abdominal surgical procedure requiring advanced 
technical and surgical skills as well as a high standard 
of pre and post-operative care. In the last two decades 
thanks to advances in anaesthesia, improvements in 
surgical techniques and postoperative care, the 
mortality rate has decreased to less than 5% [1, 2]. 
However, operative morbidity is still high with 
incidence reaching 50% in some series [2, 3, 4]. 
Traditional surgical teaching states that pancreatic 
resection should not be contemplated when pancreatic 
malignancies involve other organs, such that multi-
visceral resection would be required to remove the 
tumour. While this may be true for pancreatic ductal 
adenocarcinoma and other tumours with an aggressive 
growth pattern, for pancreatic neuroendocrine tumours 
aggressive surgical resections may achieve useful 
palliation [5] and excellent survival has been 
demonstrated with smaller locally advanced tumours 
[6, 7, 8, 9, 10]. Furthermore, such tumours often 
respond poorly to other treatment modalities [11], 
leaving surgery as the only option for treatment. 
Neuroendocrine tumours are often expected to grow 
slowly but between a third and a half of patients can 
experience aggressive local spread and metastases with 
associated debilitating symptoms and a poor outcome 
(20% 5-year survival for pancreatic neuroendocrine 
tumour metastasizing to the liver for untreated cases 
[12]). Loco- or chemo-ablative strategies while options 
for treatment for low volume disease are not as fully 
developed as for hepatocellular carcinoma and given 
the different vascular growth patterns of 
neuroendocrine tumour surgical resection (whether as 
liver transplantation or multivisceral resection) even in 
advanced disease may represent the best avenue for 
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curative intent. Several case series have reported 
success with locally advanced disease [6]. 
This study reports a series of cases of multi-visceral 
resection of large neuroendocrine tumours involving 
the pancreas at the most aggressive end of the spectrum 
of possible resections and describes the peri-operative 
and long term outcomes from these challenging 
surgical techniques. 
 
METHODS 
 
Twelve consecutive patients who underwent 
multivisceral resection of abdominal organs for 
neuroendocrine tumour involving the pancreas between 
1994 and 2008 at Southampton General Hospital were 
identified from theatre records and a surgical database. 
Multivisceral resection was defined as resection of 
pancreas and other organs not usually included in 
standard pancreatic operations, when this was required 
because of malignancy affecting both the pancreas and 
the additional organ. In this definition, the duodenum 
and distal stomach were considered part of a standard 
pancreaticoduodenectomy, and splenectomy was 
considered part of left sided pancreatectomy: these 
organs are not included in the definition of 
multivisceral resection. The surgical intention was 
radical resection in all cases. Patient data was entered 
into a study database, which was analyzed by an 
independent statistician. 
Radiological confirmation of neuroendocrine tumour 
location and suspected type was sought with 
ultrasound, barium enema, contrast-enhanced 
computed tomography (CT) and magnetic resonance 
cholangiopancreatography (MRCP). Upper GI 
endoscopy, colonoscopy and staging laparoscopy were 
also performed if required or in cases of radiological 
doubt. Radiolabelled octreotide scan was used to define 
the site and functional status. All cases were reviewed 
at a meeting involving surgeons, radiologists, and 
pathologists before proposing surgery to patients. All 
patients were followed up at 3 monthly intervals post-
discharge following surgery with clinical review and 
CT scan. If disease free at 2 years the interval between 
reviews was lengthened to yearly. 
 
ETHICS 
 
All patients were consented in a two stage process 
starting in the outpatient setting for all invasive 
procedures performed. This retrospective analysis 
conformed to the standards set out in the World 
Medical Association Declaration of Helsinki. 
 
STATISTICS 
 
Statistical analysis was performed by using MedCalc 
(Mariakerke, Belgium; version 9, for Windows XP) 
and the Statistical Package for the Social Science 
(SPSS version 12, SPSS Inc., Chicago, IL, USA) 
software. Survival rates were calculated from date of 
operation using the Kaplan-Meier method. Comparison 
of central tendency was performed using the Mann-
Whitney U, while categorical variables were compared 
by using the Fisher’s exact test. The study is 
insufficiently powered to perform logistic regression. 
Post-operative death was defined as occurring within 
ninety days of operation. Statistical significance was 
defined at the 95% level. 
 
RESULTS 
 
Demographics 
 
Twelve patients (7 men, 5 women; median age 57 
years, range: 37-79 years) underwent multi-visceral en 
bloc resections including the pancreas. Three 
consultant hepatobiliary pancreatic surgeons (MAH, 
CDJ, NWP) were involved in their care. 
 
Operative Data 
 
Three patients had resection of the pancreatic head by a 
standard Whipple’s operation; nine had left 
pancreatectomy and splenectomy. Median operative 
time was 6 hours (range: 3.0-9.3 hours) with median 
blood loss 1.1 L (range: 0.2-12 L) and median 3 (range: 
1-4) additional organs resected. Median tumour 
diameter was 9.5 cm (5-25 cm) with adequacy of 
resection and forms of invasion noted in Table 1. 
Additional organs resected are denoted in Table 2. The 
Table 1. Characteristics of patients and histology for cases with or without recurrence. 
Characteristic Recurrence (n=3) No recurrence (n=9) P-value 
Median age (range); years 55 (49-73) 57 (36-78) 0.723 a 
M:F ratio 3:0 4:5 0.204 b 
Median tumour size (range); cm 20 (8-25) 8 (5-15) 0.250 a 
Median number of  organs resected (range) 4 (2-7) 3 (2-6) 0.600 a 
Nodal involvement 1 (33.3%) 3 (33.3%) 1.000 b 
Intravascular invasion 0 2 (22.2%) 1.000 b 
R0 1 (33.3%) 3 (33.3%) 1.000 b 
Table 2. Number of resections where different organs were resected. 
Splenectomy is considered standard for distal pancreatectomy. 
Organ Number of resections involving this organ 
Colon 5 
Stomach 4 
Liver 4 
Kidney 4 
Adrenal 5 
Small bowel 4 
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typical en-bloc nature of the resected specimen is 
demonstrated in Figures 1 and 2. 
 
Complications and Mortality 
 
No post-operative (90 day) deaths occurred in this 
series and all patients were alive after median follow 
up of 24 months (4-124 months). Three patients had a 
major complication (25%); median post operative 
hospital stay was 13 days (range: 9-40 days) with only 
a small requirement for postoperative critical care stay 
(ICU median time: 1 day (range: 0-13 days); high 
dependency unit median time: 2 days (0-4 days)). Five 
patients experienced a complication; major in three 
patients (anastomotic leak, perforated colon and severe 
haemorrhage post operatively). Nevertheless, no re-
laparotomies were required. The site of haemorrhage 
was identified on CT angiography and controlled with 
formal visceral angiography and embolization. Both 
the pancreaticojejunal anastomosis leak and perforated 
colon did not lead to significant clinical deterioration 
as drains placed at the time of original laparotomy 
controlled effluent from both complications. There 
were 9 minor complications as detailed in Table 3. 
Median disease free survival was not attained (Figure 
3; the disease free interval was 24 months) and 3 
patients experienced recurrence in this series. 
Recurrence was not associated with tumour size, 
number of organs resected or margin status of the 
histological analysis (Table 1). 
 
DISCUSSION 
 
This series demonstrates that multi-visceral resection 
for even large neuroendocrine tumour involving the 
pancreas and adjacent organs can be performed safely, 
with good long term results. Multi-visceral intra-
abdominal malignancy without distant metastases 
presents an intriguing surgical problem. Previously, 
extensive local spread was a relative contraindication 
to resection due to the technical demands of surgery, 
risk of intra- or post-operative complications or death 
and expected short overall survival with or without 
surgery. This aggressive approach may increase the 
risk of mortality and postoperative complications. 
However recent reports from Japan North America and 
Europe [8, 9, 10, 11, 12, 13, 14] have demonstrated 
that good results can be achieved in selected patients 
Figure 1. Laparotomy photograph of a large neuroendocrine tumour
arising in the tail of the pancreas invading the left kidney, adrenal
and splenic flexure prior to resection. 
Figure 2. Specimen photograph from same case in Figure 1 showing 
the en-bloc resection. 
Table 3. Complications experienced in twelve patients undergoing 
multivisceral resection including the pancreas for neuroendocrine 
tumour. 
Complication Number of cases 
Patients experiencing complication 5 
Major complications: 
- Haemorrhage 
- Perforated colon 
- Anastomotic leak 
- Bile leak 
- Fistula 
 
1 
1 
1 
0 
0 
Minor complications: 
- Pneumonia 
- Intra-abdominal collection 
- Pseudomembranous colitis 
- Urine infection 
- Ileo-femoral deep venous thrombosis 
- Paralytic ileus 
- Wound sepsis 
 
2 
2 
1 
2 
1 
1 
0 
Total number of complications 12 
Figure 3. Disease free survival in twelve patients undergoing 
aggressive multivisceral resection for neuroendocrine tumour
involving the pancreas and other organs. 
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undergoing multi-visceral en bloc resections including 
the pancreas, suggesting that for extensive local spread; 
multi-visceral en bloc resection can offer acceptable 
survival rates without a high risk of early post-
operative death [5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. 
Resection of these tumours is desirable to ameliorate 
mass effects, which can be fatal [6], and to reduce the 
incidence and severity of debilitating endocrine 
symptoms. 
Patients with large pancreatic neuroendocrine tumours 
can have excellent symptom control with surgery [15, 
16] and can expect a good outcome as in this series, 
although limited in size, demonstrated no deaths after 
median follow-up of 20 months. Other recent studies 
suggest that angio-invasion may be associated with 
recurrence [6] but we did not observe this in this cohort 
and, of note, both the previous study and ours note no 
change in recurrence with size of tumour despite 
tumour size being significantly larger in our cohort [6]. 
Disease recurrence is associated with poor outcome 
and the commonest site for recurrence is the liver. 
Liver resection can be performed in selected cases [10, 
11, 12] and in some cases liver transplantation can be 
considered with the caveat of the risk of recurrence in 
the graft. In this series where a median of 3 additional 
organs were resected this included the liver in 5 cases, 
and in one a portal vein reconstruction was required in 
an aggressive resection of 6 additional organs during a 
distal pancreatectomy. The patient is still alive after 15 
months follow-up with recurrence occurring 6 months 
after surgery. It is not clear from this or other series of 
aggressive multi-visceral resection of pancreatic 
neuroendocrine tumour whether there is a ceiling of 
additional organs where resection is unlikely to provide 
an additional disease free or overall survival benefit 
and a larger series would need to be analyzed to define 
this. Of note the potentially high rate of colonic 
complications reported by other surgeons [14, 15] was 
not demonstrated here. 
Nevertheless this study has demonstrated that in 
selected patients, multivisceral resection of 
neuroendocrine tumours can be performed with low 
mortality rates by experienced pancreatic surgeons 
operating in a tertiary referral centre. These resections 
are followed by good disease-free and overall survival 
rates. Prospective collaborative studies could help 
determine optimal surgical strategies of various 
pathological subtypes and risk factors for recurrence 
and death in this novel approach to pancreatic surgery. 
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